We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
Read MoreHide Full Article
Key Takeaways
Doximity expanded AI adoption, with 140 health systems purchasing its clinical AI suite.
DOCS signed initial AI search deals with top pharma firms despite cautious ad spending trends.
OptimizeRx lowered its revenue outlook as shorter contracts and client disruption hurt visibility.
OptimizeRx Corporation (OPRX - Free Report) and Doximity, Inc. (DOCS - Free Report) both operate in the digital healthcare engagement space, helping pharmaceutical companies and healthcare providers improve communication, workflow efficiency and physician engagement through technology-driven platforms. The companies are also investing heavily in AI-enabled tools to expand their capabilities and strengthen their positions within healthcare marketing and clinical workflow ecosystems.
At the same time, both companies are navigating a challenging healthcare advertising environment marked by cautious pharmaceutical spending, shorter contract durations and macroeconomic uncertainty. Despite these near-term pressures, management at both firms emphasized continued customer engagement, expanding AI initiatives and long-term growth opportunities tied to digital healthcare transformation.
Let’s evaluate their fundamentals, growth prospects, market challenges and valuations to determine which one presents a stronger investment opportunity.
The Case for OPRX
OptimizeRx is gaining from the continued adoption of its AI-enabled DAAP solution, which grew 60% during the first quarter. The company highlighted expanding usage from major pharmaceutical clients, where point-of-prescribe solutions have evolved from targeted engagements into scaled multi-brand deployments, driven by measurable improvements in prescriber engagement and campaign performance. Management said this demonstrates the company’s ability to deepen relationships within large enterprise accounts.
OptimizeRx is also gaining from operational improvements and strategic platform expansion initiatives. The company’s DAAP subscription revenues increased 45% year over year, helping improve revenue visibility and build a more predictable financial model. OptimizeRx also announced new integrations with demand-side platforms controlling more than 80% of digital promotional spending, which management believes could drive meaningful long-term growth and improve utilization across its EHR network.
OPRX is also benefiting from growing momentum within the medtech sector and increasing adoption among mid-tier and long-tail life sciences customers. In the last earnings call, management highlighted that initial pilot programs are expanding into multimillion-dollar engagements, reinforcing confidence in the repeatability of its growth model. Management also stated that these customer groups remain significantly underpenetrated and represent a substantial long-term opportunity.
However, OptimizeRx is facing continued macroeconomic and healthcare industry headwinds that are affecting customer spending patterns. Management stated that cautious budget allocations, shorter contract durations, delays in campaign timing related to most favored nation pricing dynamics and broader macro uncertainty are reducing visibility into full-year performance. The company lowered its full-year revenue outlook to reflect these pressures. For 2026, it expects revenues to range between $95 million and $100 million, while continuing to project adjusted EBITDA between $21 million and $25 million.
Image Source: Zacks Investment Research
OptimizeRx is also dealing with a disruption tied to one major client relationship. Management stated that execution challenges within that account, combined with organizational changes at the client, contributed to weaker contracted revenue visibility. Although management in the last earnings call stated that conversations with the client have improved and the relationship is stabilizing, the disruption is expected to continue through much of 2026.
The Case for DOCS
Doximity is gaining from accelerating AI adoption and growing physician engagement across its platform. In the last earnings call, management stated that nearly half of all U.S. doctors work at hospitals using its workflow or scheduling tools, while workflow engagement reached more than 800,000 unique quarterly active prescribers, representing roughly 30% year-over-year growth. Management also stated that AI Search and Scribe users have tripled since the Pathway acquisition.
The company is benefiting from expanding adoption of its clinical AI suite among hospitals and healthcare systems. It said 140 health systems, including seven of the top 20 hospitals in the United States, have purchased its clinical AI suite, providing more than 250,000 prescribers with HIPAA-compliant AI workflows. Management highlighted strong physician preference for its AI answers in side-by-side clinical evaluations due to built-in drug references and peer-reviewed functionality.
DOCS is gaining from early traction in AI monetization opportunities. The company has already signed its first AI search agreements with the top 20 pharmaceutical manufacturers and described strong interest from pharma marketers seeking innovative AI-based engagement tools. Doximity believes AI search could represent a multibillion-dollar incremental market opportunity on top of its existing pharma advertising business.
Image Source: Zacks Investment Research
However, Doximity is grappling with softer demand conditions within the healthcare professional digital pharma advertising market. Management stated that policy uncertainty and macroeconomic concerns are leading pharmaceutical companies to make shorter-term spending commitments and maintain cautious budget strategies. The company’s visibility remains limited and it expects overall market growth to remain modest during the fiscal year.
DOCS is also experiencing margin pressure tied to elevated AI investment spending. The company noted that rising AI compute costs and increased investments in research, compute infrastructure and marketing are weighing on near-term profitability. Management expects these higher expenses to continue through fiscal 2027 as the company prioritizes long-term AI expansion initiatives.
Share Performance of OPRX & DOCS
In the past six months, OPRX stock has plunged 66% while DOCS has declined 60.3%.
Image Source: Zacks Investment Research
Valuation for OPRX & DOCS
In terms of Price/Book, OPRX shares are trading at 0.71X, lower than DOCS’ 3.94X.
Image Source: Zacks Investment Research
How Do Estimates Compare for OPRX & DOCS?
Over the past 60 days, analysts have revised their estimates downward for OPRX’s bottom line for the current year.
Image Source: Zacks Investment Research
For DOCS, estimates have been revised downward over the past 60 days.
Image Source: Zacks Investment Research
OPRX or DOCS: Which Stock Is the Better Investment?
While DOCS carries a Zacks Rank #3 (Hold) at present, OPRX has a Zacks Rank #4 (Sell). Consequently, in terms of Zacks Rank, DOCS seems to be a better option at the moment.
View the Zacks #1 Rank List
Image: Bigstock
OptimizeRx vs. Doximity: Which Digital Health Stock Is the Better Bet?
Key Takeaways
OptimizeRx Corporation (OPRX - Free Report) and Doximity, Inc. (DOCS - Free Report) both operate in the digital healthcare engagement space, helping pharmaceutical companies and healthcare providers improve communication, workflow efficiency and physician engagement through technology-driven platforms. The companies are also investing heavily in AI-enabled tools to expand their capabilities and strengthen their positions within healthcare marketing and clinical workflow ecosystems.
At the same time, both companies are navigating a challenging healthcare advertising environment marked by cautious pharmaceutical spending, shorter contract durations and macroeconomic uncertainty. Despite these near-term pressures, management at both firms emphasized continued customer engagement, expanding AI initiatives and long-term growth opportunities tied to digital healthcare transformation.
Let’s evaluate their fundamentals, growth prospects, market challenges and valuations to determine which one presents a stronger investment opportunity.
The Case for OPRX
OptimizeRx is gaining from the continued adoption of its AI-enabled DAAP solution, which grew 60% during the first quarter. The company highlighted expanding usage from major pharmaceutical clients, where point-of-prescribe solutions have evolved from targeted engagements into scaled multi-brand deployments, driven by measurable improvements in prescriber engagement and campaign performance. Management said this demonstrates the company’s ability to deepen relationships within large enterprise accounts.
OptimizeRx is also gaining from operational improvements and strategic platform expansion initiatives. The company’s DAAP subscription revenues increased 45% year over year, helping improve revenue visibility and build a more predictable financial model. OptimizeRx also announced new integrations with demand-side platforms controlling more than 80% of digital promotional spending, which management believes could drive meaningful long-term growth and improve utilization across its EHR network.
OPRX is also benefiting from growing momentum within the medtech sector and increasing adoption among mid-tier and long-tail life sciences customers. In the last earnings call, management highlighted that initial pilot programs are expanding into multimillion-dollar engagements, reinforcing confidence in the repeatability of its growth model. Management also stated that these customer groups remain significantly underpenetrated and represent a substantial long-term opportunity.
However, OptimizeRx is facing continued macroeconomic and healthcare industry headwinds that are affecting customer spending patterns. Management stated that cautious budget allocations, shorter contract durations, delays in campaign timing related to most favored nation pricing dynamics and broader macro uncertainty are reducing visibility into full-year performance. The company lowered its full-year revenue outlook to reflect these pressures. For 2026, it expects revenues to range between $95 million and $100 million, while continuing to project adjusted EBITDA between $21 million and $25 million.
Image Source: Zacks Investment Research
OptimizeRx is also dealing with a disruption tied to one major client relationship. Management stated that execution challenges within that account, combined with organizational changes at the client, contributed to weaker contracted revenue visibility. Although management in the last earnings call stated that conversations with the client have improved and the relationship is stabilizing, the disruption is expected to continue through much of 2026.
The Case for DOCS
Doximity is gaining from accelerating AI adoption and growing physician engagement across its platform. In the last earnings call, management stated that nearly half of all U.S. doctors work at hospitals using its workflow or scheduling tools, while workflow engagement reached more than 800,000 unique quarterly active prescribers, representing roughly 30% year-over-year growth. Management also stated that AI Search and Scribe users have tripled since the Pathway acquisition.
The company is benefiting from expanding adoption of its clinical AI suite among hospitals and healthcare systems. It said 140 health systems, including seven of the top 20 hospitals in the United States, have purchased its clinical AI suite, providing more than 250,000 prescribers with HIPAA-compliant AI workflows. Management highlighted strong physician preference for its AI answers in side-by-side clinical evaluations due to built-in drug references and peer-reviewed functionality.
DOCS is gaining from early traction in AI monetization opportunities. The company has already signed its first AI search agreements with the top 20 pharmaceutical manufacturers and described strong interest from pharma marketers seeking innovative AI-based engagement tools. Doximity believes AI search could represent a multibillion-dollar incremental market opportunity on top of its existing pharma advertising business.
Image Source: Zacks Investment Research
However, Doximity is grappling with softer demand conditions within the healthcare professional digital pharma advertising market. Management stated that policy uncertainty and macroeconomic concerns are leading pharmaceutical companies to make shorter-term spending commitments and maintain cautious budget strategies. The company’s visibility remains limited and it expects overall market growth to remain modest during the fiscal year.
DOCS is also experiencing margin pressure tied to elevated AI investment spending. The company noted that rising AI compute costs and increased investments in research, compute infrastructure and marketing are weighing on near-term profitability. Management expects these higher expenses to continue through fiscal 2027 as the company prioritizes long-term AI expansion initiatives.
Share Performance of OPRX & DOCS
In the past six months, OPRX stock has plunged 66% while DOCS has declined 60.3%.
Image Source: Zacks Investment Research
Valuation for OPRX & DOCS
In terms of Price/Book, OPRX shares are trading at 0.71X, lower than DOCS’ 3.94X.
Image Source: Zacks Investment Research
How Do Estimates Compare for OPRX & DOCS?
Over the past 60 days, analysts have revised their estimates downward for OPRX’s bottom line for the current year.
Image Source: Zacks Investment Research
For DOCS, estimates have been revised downward over the past 60 days.
Image Source: Zacks Investment Research
OPRX or DOCS: Which Stock Is the Better Investment?
While DOCS carries a Zacks Rank #3 (Hold) at present, OPRX has a Zacks Rank #4 (Sell). Consequently, in terms of Zacks Rank, DOCS seems to be a better option at the moment.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.